Contenido principal del artículo

Namita Singh
Integral University. Faculty of Pharmacy, Lucknow
India
Poonam Kushwaha
Integral University. Faculty of Pharmacy, Lucknow
India
Usama Ahmad
Integral University. Faculty of Pharmacy, Lucknow
India
Mohammad Abdullah
Integral University. Faculty of Pharmacy, Lucknow
India
Vol. 60 Núm. 4 (2019), Artículos de revisión, Páginas 231-240
DOI: https://doi.org/10.30827/ars.v60i4.8517
Recibido: Jan 10, 2019 Aceptado: Aug 4, 2019 Publicado: Dec 20, 2019
Derechos de autor Cómo citar

Resumen

Antecedentes: durante varios años, se han realizado muchos intentos para mejorar la estabilidad liposomal. En 1986, Payne et al, introdujeron el concepto de pro-liposoma para la preparación de liposoma con el fin de evitar la inestabilidad fisicoquímica encontrada en algunas suspensiones de liposoma tales como agregación, fusión, hidrólisis, y/o oxidación.

Objetivo: el objetivo de esta revisión es centrarse en diferentes aspectos relacionados con los Proliposomas, su método de preparación, técnicas de caracterización, asi como señalar su alcance en los sistemas de administración de fármacos.

Métodos: los Proliposomas son una nueva forma de sistemas de administración de fármacos. Son productos granulares secos y de flujo libre compuestos por fármacos y fosfolípidos que, al añaderse el agua, se dispersan para formar una suspensión liposomal multilamelar.

Resultados y discusión: estos Proliposomas son casi tan buenos o quizás mejores que los liposomas convencionales. En la presente revisión se explica brevemente el concepto de Proliposomas con un enfoque en sus componentes, preparación, caracterizaciones y su campo de aplicación.

Conclusión: una extensa encuesta de literaturas y datos recogidos sugiere que los pro-liposomas son portadores de fármacos prometedores para el futuro.

Descargas

La descarga de datos todavía no está disponible.

Detalles del artículo

Citas

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei, M, Kouhi M, NejatiKoshki K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett 2013; 8(1): 102-108.

Vyas SP, Khar RK. Liposome. In Vyas SP. Targeted and controlled drug delivery (Novel carrier systems). 2nd ed. CBS publishers and distributors, New Delhi; 2006. p.173- 181.

New RRC. Preparation of liposomes. In New RRC. Liposomes: a practical approach, 2nd ed. IRL Press: Oxford; New York; 1990. p.36-39.

Parmar G, Bala R, Seth N, Banerjee A. Proliposome: Novel drug delivery system. World J Pharm Res 2015; 4(7): 679-692.

Muneer S, Masood Z, Butt S, Anjum S, Zainab H. Proliposomes as Pharmaceutical Drug Delivery System: A Brief Review. J Nanomed Nanotechnol 2017; 8: 448-450.

Payne NI, Browning I, Hynes CA. Characterization of proliposomes. J. Pharm. Sci 1986; 75(4): 330-333.

Hiremath R, Gowda D, Raj A, Shamant BS, Srivastava A. Proliposomes: A novel approach to carrier drug delivery system. J Chem Pharm Res 2016; 8: 348-354.

Chaumeil JC. Micronization: A method of improving the bioavailability of poorly soluble drugs. Methods Find Exp. Clin. Pharmacol 1998; 20(3): 211-215.

Chen CM, Alli, D. Use of fluidized bed in proliposome manufacturing. J. Pharm. Sci 1987; 76: 419-420.

Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995; 12(3): 229-246.

Rong LJBC, Sophia YL. Liposomes in solubilisation. In Water-Insoluble drug formulation, 2nd ed.; Liu, R., Ed. CRC Press: Boca Raton, FL, USA; 2008. p. 375-416.

Betageri GV, Jenkins SA, Parsons DL. Liposome drug delivery systems. Technomic Pub. Lancaster; 1993. p.135.

Gupta V, Barupal AK, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical delivery. Indian J Pharm Sci 2008; 70: 768-775.

Shruthi MV, Parthiban S, Senthilkumar GP, Tamizmani T. Evaluation of potential hypoglycemic activity of proliposomal gel containing Metformin hydrochloride. Asian J Res Biol Pharm Sci 2014; 2(2):77-88.

Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Pow Tech 2004; 145: 139-148.

Shaji J, Bhatia V. Proliposomes: A brief overview of novel delivery system, Int Pharm Bio Sci 2013; 4(1): 150-160.

F Xia; D Hu; H jin; Y Zhao; J Liang. Food Hydrocolloids 2012: 456-463.

X Fei; J Heyang; Z Yaping; G Xinqiu. Supercritical antisolvent-based technology for preparation of vitamin D3 proliposome and its characteristics. Chinese J Chem Eng 2011;19(6): 1039-1046.

Song KH, Chung SJ, Shim CK. Preparation and evaluation of proliposomes containing salmon calcitonin. Journal of Controlled Release 2002; 84: 27-37.

Leigh M. Supra Vail Vaginal Gel. In: Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts (eds.), Modified-Release Drug Delivery Technology, Marcel Dekker, NewYork; 2003. p. 791-800.

Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgesterel for effective contraception. J Control Release 1998; 54:149–65.

Potluri, P, Betageri GV. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv 2006; 13(3): 227-232.

Bobbala SK, Veerareddy PR. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J. Liposome Res 2012; 22(4): 285-294.

Vemuri S, Rhodes C. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Ac Hel 1995; 70: 95-111.

Riaz, M. Liposomes preparation methods. Pak. J. Pharm. Sci 1996; 9(1): 65-77.

Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54:131–155.

Katare OP.; Vyas SP, Dixit VK. Proliposomes of indomethacin for oral administration. J. Microencapsul 1991; 8(1): 1-7.

Yadav A, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposomes. Ind J Pha Edu Res 2011; 45: 402-413.

Chu C, Tong SS, Xu Y, Wang L. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin 2011; 32(7): 973-980.

Dhurke R, Nalla P, Bagam S, Eedara BB. Formulation and evaluation of domperidone oral proliposomal powders. Int J PharmTech Res 2015; 7(1):108-118

Chuandi Sun, Ji Wang, Jianping Liu, Wenli zhang. Liquid proliposomes of Nimodipine drug delivery system: Preparation, characterization, and pharmacokinetic. AAPS Pharm Sci Tech 2013;14(1):332-338.

Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based transdermal delivery of levonorgestrel. J Biomat App 1997; 12:77–88.

Jukanti R, Sheela S, Bandari S, Veerareddy PR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci 2011; 100: 3208-3222.

Jain SK, Jain NK. Controlled and novel drug delivery. CBS publishers and distributors, Delhi 2003: 304-341.

Hwang BY, Jung BH, Chung SJ, Lee MH, Shim CK. In vitro skin permeation of nicotine from proliposomes. J Control Release 1997; 49: 177-184.

Kumara BC, Parthiban S, Senthil Kumar GP, Tamiz Mani T, Formulation and Evaluation of Proliposomal Gel Containing Repaglinide Using Mannitol as Water Soluble Carrier. Imperial Journal of Interdisciplinary Research 2016; 2(5):1777-1786.

Kurakula M, Srinivas C, Kasturi N, Diwan PV. Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. Int J Pharm Sci Drug Res 2012; 4(1):35-43.

Kurakula M, Pasula, N. Piroxicam proliposomal gel -A novel approach for topical delivery. J Pharm Res 2012;5 (3):1755.

Ning MY, Guo YZ, Pan HZ, Yu HM. Preparation and evaluation of proliposomes containing Clotrimazole. Chem Pharm bull, 2005; 53(6):620-624.

Chougule M, Padhi BJ, Misra A. Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS Pharm Sci Tech 2008, 9(1), 47-53.

Kaur PI, Garg A, Singla KA. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004; 269: 1- 14.

Karn PR, Kim HD, Kang H, Sun BK, Jin SE, Hwang SJ. Preparation and evaluation of cyclosporin a-containing proliposomes: a comparison of the supercritical antisolvent process with the conventional film method. Int J Nanomed 2014:9 5079–5091.

Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009; 4: 299–319.

Rojanarat W, Nakpheng T, Thawithong E, Yanyium N. Levofloxacin-Proliposomes: Opportunities for use in lung Tuberculosis. Pharmaceutics 2012; 4:385-412.

Patil A, Pokharkar GV. Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Pulmonary Pharmacol Therapeutics 2014; 27(2):197-207.

Kajornwongwattana W, Changsan N, Tawithong E, Srichana T. Isoniazid Proliposome Powders for Inhalation-Preparation, Characterization and Cell Culture Studies. International Journal of Molecular Sciences 2011; 12(7):4414-4434.

Parmar JJ, Singh DJ, Hegde DD, Menon M. Development and Evaluation of Inhalational Liposomal System of Budesonide for Better Management of Asthma. Indian Journal of Pharmaceutical Sciences 2010; 72(4):442-448.

Zeng XM, Martin GP, Marriott. The controlled delivery of drugs to the lung. International Journal of Pharmaceutics 1995; 124(2):149–164.

Ugwoke M I, Agu R U, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives, Adv Drug Del Rev 2005; 57.

Shin BN, Chang KK, Shim K. Proliposomes as an intranasal dosage form for the sustained delivery of propranolol. Journal of Controlled Release 1995;34(3): 203-210.

Jung BH, Chung SJ, Shim CK. Proliposomes as prolonged intranasal drug delivery systems. STP Pharma Sci 2002; 12(1): 33-38.

Jung BH, Chung BC, Chung SJ, Shim CK. Prolonged delivery of nicotine in rats via nasal administration of proliposomes. J Control Rel 2000; 66(1):73-79.

Park JM, Ahn BN, Yoon EJ, Lee MG, Shim CK, Kim CK. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. Biopharm Drug Dispos 1994; 15(5): 391-407.

Katare, OP, Vyas SP, Dixit VK. Effervescent granule based proliposomes of ibuprofen. J Microencapsul 1990; 7(4): 455-460.